45th NANOS Annual Meeting, Las Vegas, Nevada, US

World Orphan Drug Congress Europe, Barcelona, Spain

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics provides an update on the clinical and regulatory pathways for GS010

Ophthalmology Innovation Summit @ AAO, Chicago (IL)

American Academy of Ophthalmology, Chicago (IL)

Key Opinion Leaders highlight GS010 efficacy and patient benefits in discussion of findings from REVERSE Phase III clinical trial

GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Host KOL Event on June 12, 2018 in New York City